story of the week
Fulvestrant 500 mg Versus Anastrozole 1 mg for Hormone Receptor–Positive Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fulvestrant 500 mg Versus Anastrozole 1 mg for Hormone Receptor-Positive Advanced Breast Cancer (FALCON): An International, Randomised, Double-Blind, Phase 3 Trial
Lancet 2016 Nov 28;[EPub Ahead of Print], JF Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, A Manikhas, Y Shparyk, S Cardona-Huerta, KL Cheung, MJ Philco-Salas, M Ruiz-Borrego, Z Shao, S Noguchi, J Rowbottom, M Stuart, LM Grinsted, M Fazal, MJ EllisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.